EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT

Dédée F Murrell, Pascal Joly, Victoria P Werth, Hideyuki Ujiie, Margitta Worm, Aaron R Mangold, Elena Avetisova, Jennifer Maloney, Elizabeth Laws, Eric Mortensen, Ariane Dubost-Brama, Arsalan Shabbir

Advances in Therapy · 2024-07 · 41 (7) · 2991-3002

DOI: 10.1007/s12325-024-02810-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, online erschienen am 05.03.2024. Verfasst von Dédée F Murrell und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St George Hospital, University of New South Wales, Sydney, NSW, Australia. d.murrell@unsw.edu.au. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Pemphigoid, Bullous. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals, University of New South Wales.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPemphigoid, BullousAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodTreatment OutcomeRandomized Controlled Trials as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

Autoimmune blistering disorderBullous pemphigoidDupilumabOral corticosteroids

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Dermatology, St George Hospital, University of New South Wales, Sydney, NSW, Australia. d.murrell@unsw.edu.au.
  • The Church, 17 Kensington St, Kogarah, NSW, 2217, Australia. d.murrell@unsw.edu.au.
  • Rouen University Hospital and INSERM 1234, Normandy University, Rouen, France.
  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.
  • Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

Förderung

  • Sanofi
  • Regeneron Pharmaceuticals
  • University of New South Wales

Zitieren

APA

Murrell, D. F., Joly, P., Werth, V. P., Ujiie, H., Worm, M., Mangold, A. R., Avetisova, E., Maloney, J., Laws, E., Mortensen, E., Dubost-Brama, A., & Shabbir, A. (2024). Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT. Advances in Therapy, 41(7), 2991-3002. https://doi.org/10.1007/s12325-024-02810-3

Vancouver

Murrell DF, Joly P, Werth VP, Ujiie H, Worm M, Mangold AR, et al. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT. Advances in Therapy. 2024;41(7):2991-3002. doi:10.1007/s12325-024-02810-3

BibTeX
@article{Murrell2024,
  author = {Murrell, Dédée F and Joly, Pascal and Werth, Victoria P and Ujiie, Hideyuki and Worm, Margitta and Mangold, Aaron R and Avetisova, Elena and Maloney, Jennifer and Laws, Elizabeth and Mortensen, Eric and Dubost-Brama, Ariane and Shabbir, Arsalan},
  title = {Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT},
  journal = {Advances in Therapy},
  year = {2024},
  volume = {41},
  number = {7},
  pages = {2991--3002},
  doi = {10.1007/s12325-024-02810-3}
}
Kostenlos starten →